As part of its redeployment of about $20 million in capital from preclinical and noncardiac pipeline activities to its lead cardiac programs, Lexeo Therapeutics in April laid off roughly 15% of its employees, the company announced May 12. The New York–based biotech had 75 full-time employees as of March 31, according to an SEC filing, meaning the layoffs could affect around 11 employees.
